Trellis Bioscience to Provide Cell Line Development Services to PDL BioPharma Using Proprietary Antibody CellSpot(TM) Technology
Posted on: Monday, 6 February 2006, 12:00 CST
SOUTH SAN FRANCISCO, Calif., Feb. 6 /PRNewswire/ -- Trellis Bioscience today announced that it has signed an agreement with PDL BioPharma to provide cell line development services using Trellis' Antibody CellSpot(TM) technology.
Antibody CellSpot(TM) allows for in-depth analysis and characterization of millions of individual antibody-producing cells for multiple properties, such as the affinity, specificity and secretion rate, and is coupled to a proprietary method for harvesting single cells. The platform can screen diverse libraries of cells at an unprecedented level of depth and detail and operates with a simplicity and speed that can shave months from the normal development and manufacturing cycle for an antibody candidate.
"Our work with PDL BioPharma will allow us to demonstrate the power of CellSpot(TM). PDL BioPharma is a world leader in the discovery and development of antibodies, and we are excited to be working with them," said Nolan Sigal, M.D., Ph.D., President of Trellis Bioscience.
About Trellis Bioscience:
Trellis Bioscience is a South San Francisco biotechnology company that has developed a breakthrough technology for the characterization of individual live cells in unprecedented detail. The Trellis proprietary technology, including patents and know-how, uses nanoparticles, software and digital microscopy in a live cell environment to achieve multiplexing and miniaturization in one step. This capability enables a qualitatively new approach to the detection and propagation of rare events within an antibody- producing cell population, facilitating the discovery and development of better therapeutic antibodies, faster than by current methods. This capability addresses key bottlenecks in the discovery of novel therapeutic antibodies as well as in the generation of high-secreting cell lines for manufacturing. Trellis currently is working with biopharmaceutical companies on discovery and development of antibodies and recombinant proteins, and is generating an internal pipeline of native human monoclonals in infectious disease and oncology.
For more information, go to http://www.trellisbio.com/.
Trellis Bioscience
CONTACT: Nolan Sigal of Trellis Bioscience, +1-650-616-1122, ornsigal@trellisbio.com
Web site: http://www.trellisbio.com/
Source: PRNewswire
Related Articles
- Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
- Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
- Affitech Reports Milestone Achievement in Antibody Discovery Partnership
- Affitech Announces Achievement of Significant Milestone in Antibody Discovery Collaboration
- Raven Biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
- Trellis Bioscience Discovers Anti-RSV Monoclonal Antibodies Isolated Directly From Human Blood Cells
- Developments in Stem Cell Research - Progenitor Cells Inspire a Therapy for Renal Failure
- Dyax Corp. And Glenmark Enter Into Funded Research Agreement for Discovery of Therapeutic Antibodies
- BioInvent Enters Collaboration With Genentech to Develop and Commercialize BioInvent's Proprietary Antibody for the Potential Treatment of Cardiovascular Diseases
 |
 |
User Comments (0)
RSS Feeds